Dana Bageon
Psychiatric/Mental Health · Wayzata, MNNPI 1417205949
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.1% of the total across 289 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,439 and has fallen 81.6% since, to $449 in 2025. Among psychiatric/mental health clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 289 payments — averaging $25.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$1K
- GSK$845
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$387
- Lilly USA, LLC$343
- Johnson & Johnson$331
- plus $3K from 25 others
What the payments were for
- Food & beverage$7,15097%
- Education$2103%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 56 | $1,468 |
| AbbVie | 60 | $1,205 |
| GSK | 38 | $845 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $387 |
| Lilly USA, LLC | 18 | $343 |
| Johnson & Johnson | 13 | $331 |
| AstraZeneca | 14 | $324 |
| Boehringer Ingelheim | 16 | $254 |
| Bayer | 12 | $244 |
| Tris Pharma Inc | 2 | $242 |
| Astellas Pharma US Inc | 5 | $240 |
| Amgen | 2 | $239 |
| Abiomed | 1 | $143 |
| Novartis | 8 | $140 |
| Pfizer | 8 | $125 |
| Gilead | 1 | $125 |
| Currax Pharmaceuticals LLC | 7 | $108 |
| Medtronic | 1 | $101 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $82 |
| Dexcom, Inc. | 2 | $61 |
| Merck | 3 | $59 |
| Alkermes, Inc. | 2 | $57 |
| Esperion Therapeutics, Inc. | 3 | $46 |
| Axsome Therapeutics, Inc. | 1 | $37 |
| Biohaven Pharmaceuticals, Inc. | 2 | $34 |
| Exact Sciences | 2 | $28 |
| Silk Road Medical, Inc. | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$387
- Dyanavel XR$242
- Quillivant$242
- Quillichew ER$242
- VRAYLAR$241
- Repatha$239
- RYBELSUS$227
- UBRELVY$125
- Epclusa$125
- Saxenda$122
- TRELEGY ELLIPTA$115
- AREXVY$113
- XARELTO$110
- Wegovy$106
- ENDURANT IIS$101
How this compares
$7,360 in reported general payments places this provider in the 95th percentile of 407 psychiatric/mental health providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 16 | $21,770 |
| EliquisApixaban | 20 | $19,572 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 45 | $941 |
| Omeprazole | 41 | $655 |
| Losartan Potassium | 72 | $609 |
| Metoprolol Succinate | 40 | $582 |
| Potassium Chloride | 34 | $509 |
| Atorvastatin Calcium | 68 | $492 |
| Tamsulosin Hcl | 25 | $426 |
| Pantoprazole Sodium | 40 | $390 |
| Amlodipine Besylate | 80 | $385 |
| Levothyroxine Sodium | 27 | $378 |
| Amitriptyline Hcl | 15 | $362 |
| Lisinopril | 48 | $275 |
| FenofibrateFenofibrate Nanocrystallized | 12 | $265 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $254 | $21,77016 claims |
| PfizerEliquis | $125 | $19,57220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 407 psychiatric/mental health providers in Minnesota.
Other psychiatric/mental health in Wayzata
- Jacqualine GervaisMoorhead$29K
- Naomi KoenigSandstone$8K
- Jill ScottAnoka$5K
- Holly WillisMinneapolis$5K
- Gerard BalanMinneapolis$5K
- Hilary BreedonShakopee$3K
- Tina AlexanderEdina$3K
- Twilla OskeyBaxter$3K
- Sara OckerCambridge$3K
- Patrick DixonAnoka$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.